Skip to main content

Table 2 Clinical and Lung Function Parameters of the trial participants at study entry

From: Home telemonitoring for patients with acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial

 

TM group

n = 230

Control group

n = 104

P

MRC Dyspnea Score [No of participants (%)]

  

0.64

 • Level 1

26 (11.30%)

10 (9.62%)

 

 • Level 2

60 (26.09%)

32 (30.77%)

 

 • Level 3

65 (28.26%)

25 (24.04%)

 

 • Level 4

53 (23.04%)

29 (27.88%)

 

 • Level 5

26 (11.30%)

8 (7.69%)

 

CAT Score [mean (SD)]

15.23 (8.21)

14.00 (6.82)

0.37

HADS Score [mean (SD)]

 • Anxiety

4.68 (3.45)

5.4 (3.35)

0.09

 • Depression

5.1 (4.42)

5.48 (4.49)

0.6

SF36v2

   

 • PCS

38.36 (9.79)

37.33 (9.42)

0.42

 • MCS

44.78 (11.29)

44.57 (11.42)

0.88

Cardiovascular comorbidity [No of participants (%)]

  

0.63

 • Hypertension, n

94 (61.04%)

51 (64.56%)

 

 • Ischemic Heart Disease, n

60 (38.96%)

28 (35.44%)

 

Prescribed medication [No of participants (%)]

 • LABA

221 (97.79%)

96 (94.12%)

0.11

 • LAMA

197 (87.17%)

88 (86.27%)

1

 • Inhaled steroid

192 (83.48%)

80 (76.92%)

0.18

 • Systemic steroid

15 (6.52%)

5 (4.81%)

0.36

LTOT [No of participants (%)]

95 (41.30%)

41 (39.42%)

0.76

Pulmonary Function Test [mean (SD)]

   

 • FEV1, L

1.06 (0.59)

1.09 (0.54)

0.99

 • FEV1, %

41.90 (8.64)

41.87 (8.30)

0.56

Arterial Blood Gas [mean (SD)]

 • PCO2, mmHg

44.31 (7.64)

48.85 (9.28)

<0.004

 • PO2, mmHg

65.65 (9.89)

65.01 (10.98)

0.81

6-min WT, mt [mean (SD)]

263.4 (95.9)

213.1 (109.4)

0.32

  1. Data are presented as Numbers or Means (SD)
  2. FEV 1 Forced Expiratory Volume in the first second, HADS Hospital Anxiety and Depression Scale, LABA Long-Acting β2-Agonist, LAMA Long-Acting Muscarinic Antagonist, LTOT Long-Term use of Oxygen Therapy, MCS mental component summary, PCS physical component summary, TM telemonitoring, 6-min WT 6-minute Walking Test